Trial Profile
Phase I Trial of Intravenous Administration of Vesicular Stomatitis Virus Genetically Engineered to Express Thyroidal Sodium Iodide Symporter (NIS) and Human Interferon Beta (hIFNb), in Patients With Metastatic or Recurrent Endometrial Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 29 Jan 2024
Price :
$35
*
At a glance
- Drugs VSV-IFNbeta-NIS (Primary) ; Ruxolitinib; Technetium-99m
- Indications Adenocarcinoma; Carcinoma; Endometrial cancer; Sarcoma
- Focus Adverse reactions
- 22 Jan 2024 Status changed from recruiting to active, no longer recruiting.
- 29 Aug 2023 Status changed from active, no longer recruiting to recruiting.
- 17 May 2023 Planned End Date changed from 15 Jul 2023 to 15 Jul 2024.